{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:15:06Z","timestamp":1789193706815,"version":"build-2803163510"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cbi.2021.109566","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:37:24Z","timestamp":1624444644000},"page":"109566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism"],"prefix":"10.1016","volume":"345","author":[{"given":"Yun-Qing","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Bo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2021.109566_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cbi.2016.02.011","article-title":"Carboxylesterases: general detoxifying enzymes","volume":"259","author":"Hatfield","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2021.109566_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.pharmtox.38.1.257","article-title":"The mammalian carboxylesterases: from molecules to functions","volume":"38","author":"Satoh","year":"1998","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jbt.20178","article-title":"Human Carboxylesterases and their role in xenobiotic and endobiotic metabolism","volume":"21","author":"Ross","year":"2007","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem. Biol. Interact."},{"issue":"9\u201310","key":"10.1016\/j.cbi.2021.109566_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00335-010-9284-4","article-title":"Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins","volume":"21","author":"Holmes","year":"2010","journal-title":"Mamm. Genome"},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1359-6446(05)03383-0","article-title":"Mammalian carboxylesterases: from drug targets to protein therapeutics","volume":"10","author":"Redinbo","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bcp.2008.10.005","article-title":"Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin","volume":"77","author":"Yang","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.cbi.2021.109566_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138920010794328904","article-title":"The role of intestinal carboxylesterase in the oral absorption of prodrugs","volume":"11","author":"Imai","year":"2010","journal-title":"Curr. Drug Metabol."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/molecules13020412","article-title":"Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs","volume":"13","author":"Hosokawa","year":"2008","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2133\/dmpk.21.173","article-title":"Human carboxylesterase isozymes: catalytic properties and rational drug design","volume":"21","author":"Imai","year":"2006","journal-title":"Drug Metabol. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.cbi.2021.109566_bib13","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1124\/dmd.106.009381","article-title":"Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine","volume":"34","author":"Imai","year":"2006","journal-title":"Drug Metabol. Dispos."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13238-017-0437-z","article-title":"Carboxylesterases in lipid metabolism: from mouse to human","volume":"9","author":"Lian","year":"2018","journal-title":"Protein Cell"},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1584\/jpestics.R10-07","article-title":"Carboxylesterases: dual roles in lipid and pesticide metabolism","volume":"35","author":"Ross","year":"2010","journal-title":"J. Pestic. Sci."},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jmb.2006.08.025","article-title":"Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1","volume":"363","author":"Bencharit","year":"2006","journal-title":"J. Mol. Biol."},{"issue":"9","key":"10.1016\/j.cbi.2021.109566_bib17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/0006-2952(94)90461-8","article-title":"Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine","volume":"48","author":"Brzezinski","year":"1994","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.cbi.2021.109566_bib18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1248\/bpb.20.869","article-title":"Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver","volume":"20","author":"Takai","year":"1997","journal-title":"Biol. Pharmaceut. Bull."},{"key":"10.1016\/j.cbi.2021.109566_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1042\/bst0310620","article-title":"Human carboxylesterase 1: from drug metabolism to drug discovery","volume":"31","author":"Redinbo","year":"2003","journal-title":"Biochem. Soc. Trans."},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1074-5521(03)00071-1","article-title":"Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition","volume":"10","author":"Bencharit","year":"2003","journal-title":"Chem. Biol."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nsb919","article-title":"Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme","volume":"10","author":"Bencharit","year":"2003","journal-title":"Nat. Struct. Biol."},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jmb.2005.07.016","article-title":"Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil","volume":"352","author":"Fleming","year":"2005","journal-title":"J. Mol. Biol."},{"issue":"16","key":"10.1016\/j.cbi.2021.109566_bib23","first-page":"3627","article-title":"Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme","volume":"58","author":"Potter","year":"1998","journal-title":"Canc. Res."},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bmc.2009.10.052","article-title":"In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations","volume":"18","author":"Vistoli","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.cbi.2021.109566_bib25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10822-010-9373-1","article-title":"Homology modeling and metabolism prediction of human carboxylesterase-2 using docking analyses by GriDock: a parallelized tool based on AutoDock 4.0","volume":"24","author":"Vistoli","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"7","key":"10.1016\/j.cbi.2021.109566_bib26","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1021\/acssensors.0c00384","article-title":"Bioluminescent sensor reveals that carboxylesterase 1A is a novel endoplasmic reticulum-derived serologic indicator for hepatocyte injury","volume":"5","author":"Wang","year":"2020","journal-title":"ACS Sens."},{"key":"10.1016\/j.cbi.2021.109566_bib27","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1021\/acs.molpharmaceut.0c00559","article-title":"Characterization of differential tissue abundance of major non-CYP enzymes in human","volume":"17","author":"Basit","year":"2020","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/dmd.116.072652","article-title":"Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS\/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants","volume":"45","author":"Boberg","year":"2017","journal-title":"Drug Metabol. Dispos."},{"issue":"10","key":"10.1016\/j.cbi.2021.109566_bib29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbalip.2008.07.005","article-title":"Inhibition of carboxylesterase 1 is associated with cholesteryl ester retention in human THP-1 monocyte\/macrophages","volume":"1781","author":"Crow","year":"2008","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"10","key":"10.1016\/j.cbi.2021.109566_bib30","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/jps.23258","article-title":"Species difference of esterase expression and hydrolase activity in plasma","volume":"101","author":"Bahar","year":"2012","journal-title":"J. Pharmaceut. Sci."},{"issue":"11","key":"10.1016\/j.cbi.2021.109566_bib31","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","article-title":"Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma","volume":"70","author":"Li","year":"2005","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1006\/bbrc.2002.6547","article-title":"Proteome analysis of hepatocellular carcinoma","volume":"291","author":"Lim","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.86.1.322","article-title":"Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase","volume":"86","author":"Satoh","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.cbi.2021.109566_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103388","article-title":"Detection techniques of carboxylesterase activity: an update review","volume":"94","author":"Lan","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"15","key":"10.1016\/j.cbi.2021.109566_bib35","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1039\/C5CC09874B","article-title":"A bioluminescent sensor for highly selective and sensitive detection of human carboxylesterase 1 in complex biological samples","volume":"52","author":"Wang","year":"2016","journal-title":"Chem. Commun."},{"issue":"6","key":"10.1016\/j.cbi.2021.109566_bib36","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jps.20542","article-title":"Enzymes involved in the bioconversion of ester-based prodrugs","volume":"95","author":"Liederer","year":"2006","journal-title":"J. Pharmaceut. Sci."},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.cgt.7701112","article-title":"An improved human carboxylesterase for enzyme\/prodrug therapy with CPT-11","volume":"15","author":"Wierdl","year":"2008","journal-title":"Canc. Gene Ther."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1124\/jpet.111.188508","article-title":"Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity","volume":"340","author":"Wong","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2021.109566_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389200219666180821094502","article-title":"The impact of carboxylesterases in drug metabolism and pharmacokinetics","volume":"20","author":"Di","year":"2019","journal-title":"Curr. Drug Metabol."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","author":"Farid","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.113.054353","article-title":"Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis","volume":"42","author":"Laizure","year":"2014","journal-title":"Drug Metabol. Dispos."},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/dmd.113.053512","article-title":"In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors","volume":"42","author":"Thomsen","year":"2014","journal-title":"Drug Metabol. Dispos."},{"issue":"1\u20132","key":"10.1016\/j.cbi.2021.109566_bib43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0731-7085(01)00508-8","article-title":"Kinetics of the acidic and enzymatic hydrolysis of benazepril HCl studied by LC","volume":"27","author":"Gana","year":"2002","journal-title":"J. Pharmaceut. Biomed. Anal."},{"issue":"12","key":"10.1016\/j.cbi.2021.109566_bib44","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1124\/dmd.110.034454","article-title":"In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities","volume":"38","author":"Fukami","year":"2010","journal-title":"Drug Metabol. Dispos."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib45","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1248\/bpb.b14-00679","article-title":"Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin","volume":"38","author":"Wang","year":"2015","journal-title":"Biol. Pharmaceut. Bull."},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib46","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1124\/jpet.106.111807","article-title":"Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel","volume":"319","author":"Shi","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nsb790","article-title":"Structural insights into CPT-11 activation by mammalian carboxylesterases","volume":"9","author":"Bencharit","year":"2002","journal-title":"Nat. Struct. Biol."},{"issue":"12","key":"10.1016\/j.cbi.2021.109566_bib48","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1124\/dmd.110.034249","article-title":"Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil","volume":"38","author":"Fujiyama","year":"2010","journal-title":"Drug Metabol. Dispos."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00498250902769967","article-title":"In vitro stability and metabolism of salvinorin A in rat plasma","volume":"39","author":"Tsujikawa","year":"2009","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib50","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.115.068536","article-title":"Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation","volume":"44","author":"Shi","year":"2016","journal-title":"Drug Metabol. Dispos."},{"issue":"7","key":"10.1016\/j.cbi.2021.109566_bib51","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0006-2952(96)00457-1","article-title":"Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase","volume":"52","author":"Rivory","year":"1996","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib52","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1248\/bpb.17.662","article-title":"Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase","volume":"17","author":"Satoh","year":"1994","journal-title":"Biol. Pharmaceut. Bull."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib53","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1078-0432.CCR-12-1184","article-title":"Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells","volume":"19","author":"Pratt","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.cbi.2021.109566_bib54","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2011-2981","article-title":"Carboxylesterase 2 hydrolyzes a gemcitabine prodrug (LY2334737) and provides a patient tailoring biomarker","volume":"71","author":"Pratt","year":"2011","journal-title":"Canc. Res."},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1515\/dmdi-2014-0009","article-title":"The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect","volume":"29","author":"Merali","year":"2014","journal-title":"Drug Metabol. Drug Interact."},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.112.201640","article-title":"Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation","volume":"344","author":"Zhu","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib57","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.104.067116","article-title":"Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1","volume":"310","author":"Sun","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib58","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0022-3565(25)21180-6","article-title":"Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases","volume":"279","author":"Kamendulis","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"23","key":"10.1016\/j.cbi.2021.109566_bib59","doi-asserted-by":"crossref","first-page":"14769","DOI":"10.1074\/jbc.272.23.14769","article-title":"Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin","volume":"272","author":"Pindel","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2021.109566_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejps.2015.07.006","article-title":"Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases","volume":"78","author":"Fukami","year":"2015","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"9","key":"10.1016\/j.cbi.2021.109566_bib61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1291\/hypres.28.719","article-title":"A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity","volume":"28","author":"Geshi","year":"2005","journal-title":"Hypertens. Res."},{"issue":"7594","key":"10.1016\/j.cbi.2021.109566_bib62","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib63","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cclet.2018.12.013","article-title":"Sensing carboxylesterase 1 in living systems by a practical and isoform-specific fluorescent probe","volume":"30","author":"Ding","year":"2019","journal-title":"Chin. Chem. Lett."},{"issue":"9","key":"10.1016\/j.cbi.2021.109566_bib64","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1021\/acs.analchem.8b05417","article-title":"Rational design of a long-wavelength fluorescent probe for highly selective sensing of carboxylesterase 1 in living systems","volume":"91","author":"Tian","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cbi.2021.109566_bib65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bios.2016.04.075","article-title":"A highly selective near-infrared fluorescent probe for carboxylesterase 2 and its bioimaging applications in living cells and animals","volume":"83","author":"Jin","year":"2016","journal-title":"Biosens. Bioelectron."},{"issue":"15","key":"10.1016\/j.cbi.2021.109566_bib66","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1021\/acs.analchem.8b02101","article-title":"Carboxylesterase-2-Selective two-photon ratiometric probe reveals decreased carboxylesterase-2 activity in breast cancer cells","volume":"90","author":"Park","year":"2018","journal-title":"Anal. Chem."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib67","first-page":"105","article-title":"Research progress in specific probe substrates for drug metabolizing enzymes","volume":"41","author":"Wang","year":"2017","journal-title":"Progr. Pharmaceut. Sci."},{"key":"10.1016\/j.cbi.2021.109566_bib68","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.fitote.2017.01.010","article-title":"Recent progress in the discovery of natural inhibitors against human carboxylesterases","volume":"117","author":"Wang","year":"2017","journal-title":"Fitoterapia"},{"issue":"7","key":"10.1016\/j.cbi.2021.109566_bib69","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.bcp.2008.12.017","article-title":"Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril","volume":"77","author":"Zhu","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.cbi.2021.109566_bib70","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1039\/C5RA23614B","article-title":"A highly selective marker reaction for measuring the activity of human carboxylesterase 1 in complex biological samples","volume":"6","author":"Lv","year":"2016","journal-title":"RSC Adv."},{"issue":"6","key":"10.1016\/j.cbi.2021.109566_bib71","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1124\/dmd.30.6.643","article-title":"Involvement of liver carboxylesterases in the in vitro metabolism of lidocaine","volume":"30","author":"Alexson","year":"2002","journal-title":"Drug Metabol. Dispos."},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib72","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0022-3565(24)34901-8","article-title":"Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1","volume":"290","author":"Zhang","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib73","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1124\/jpet.104.081265","article-title":"Hydrolysis of capecitabine to 5 '-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide","volume":"313","author":"Quinney","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6","key":"10.1016\/j.cbi.2021.109566_bib74","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1124\/dmd.112.044537","article-title":"Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver","volume":"40","author":"Kobayashi","year":"2012","journal-title":"Drug Metabol. Dispos."},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib75","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/tpj.2015.42","article-title":"CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors","volume":"16","author":"Wang","year":"2016","journal-title":"Pharmacogenomics J."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib76","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/bcp.12667","article-title":"Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril","volume":"80","author":"Tarkiainen","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib77","first-page":"38","article-title":"Isolation and pharmacological characterization of microsomal human liver flumazenil carboxylesterase","volume":"1","author":"Kleingeist","year":"1998","journal-title":"J. Pharm. Pharmaceut. Sci.: Publ. Canadian Soc. Pharmaceu. Sci. Soc. Canadienne Sci. Pharmaceut."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib78","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/dmd.111.043208","article-title":"Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver","volume":"40","author":"Sato","year":"2012","journal-title":"Drug Metabol. Dispos."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib79","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.xphs.2018.09.022","article-title":"Contribution of human liver and intestinal carboxylesterases to the hydrolysis of selexipag in vitro","volume":"108","author":"Imai","year":"2019","journal-title":"J. Pharmaceut. Sci."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib80","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/00498254.2017.1333658","article-title":"Predominant contributions of carboxylesterase 1 and 2 in hydrolysis of anordrin in humans","volume":"48","author":"Jiang","year":"2018","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.cbi.2021.109566_bib81","first-page":"600","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Caterina","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.cbi.2021.109566_bib82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/IBPC.S12215","article-title":"Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor management","volume":"4","author":"Zamorano","year":"2011","journal-title":"Integrated Blood Pres. Contr."},{"issue":"6","key":"10.1016\/j.cbi.2021.109566_bib83","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2133\/dmpk.DMPK-12-RG-143","article-title":"Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro","volume":"28","author":"Xu","year":"2013","journal-title":"Drug Metabol. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib84","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/dmd.108.024331","article-title":"Different inhibitory effects in rat and human carboxylesterases","volume":"37","author":"Takahashi","year":"2009","journal-title":"Drug Metabol. Dispos."},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib85","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bbrc.2015.04.145","article-title":"The anti-hypertensive drug reserpine induces neuronal cell death through inhibition of autophagic flux","volume":"462","author":"Lee","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cbi.2021.109566_bib86","doi-asserted-by":"crossref","first-page":"104367","DOI":"10.1016\/j.bioorg.2020.104367","article-title":"Discovery of natural alkaloids as potent and selective inhibitors against human carboxylesterase 2","volume":"105","author":"Zhao","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"2\u20133","key":"10.1016\/j.cbi.2021.109566_bib87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tox.2010.01.009","article-title":"Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions","volume":"270","author":"Zhu","year":"2010","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib88","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s11095-011-0637-9","article-title":"Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions","volume":"29","author":"Rhoades","year":"2012","journal-title":"Pharmaceut. Res."},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib89","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/bc015588t","article-title":"Identification of two tamoxifen target proteins by photolabeling with 4-(2-morpholinoethoxy) benzophenone","volume":"13","author":"Mesange","year":"2002","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.cbi.2021.109566_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2016.11.004","article-title":"Biopharmaceutical aspects and implications of excipient variability in drug product performance","volume":"111","author":"Zarmpi","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib91","article-title":"In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2","volume":"9","author":"Zhang","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.cbi.2021.109566_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2013.00177","article-title":"The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety","volume":"4","author":"Ekor","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109566_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2020.104159","article-title":"Pentacyclic triterpenoid acids in Styrax as potent and highly specific inhibitors against human carboxylesterase 1A","author":"Wang","year":"2020","journal-title":"Food Func."},{"key":"10.1016\/j.cbi.2021.109566_bib94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.fitote.2016.09.022","article-title":"Identification and characterization of naturally occurring inhibitors against human carboxylesterase 2 in White Mulberry Root-bark","volume":"115","author":"Liu","year":"2016","journal-title":"Fitoterapia"},{"key":"10.1016\/j.cbi.2021.109566_bib95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.fitote.2015.01.004","article-title":"Fructus Psoraleae contains natural compounds with potent inhibitory effects towards human carboxylesterase 2","volume":"101","author":"Li","year":"2015","journal-title":"Fitoterapia"},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib96","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1021\/np300628a","article-title":"Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza (\"Danshen\")","volume":"76","author":"Hatfield","year":"2013","journal-title":"J. Nat. Prod."},{"issue":"7","key":"10.1016\/j.cbi.2021.109566_bib97","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/jphp.12055","article-title":"Effects of herbal supplements on the bioactivation of chemotherapeutic agents","volume":"65","author":"Gorman","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"issue":"7","key":"10.1016\/j.cbi.2021.109566_bib98","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.114.056994","article-title":"Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase","volume":"42","author":"Shimizu","year":"2014","journal-title":"Drug Metabol. Dispos."},{"issue":"11","key":"10.1016\/j.cbi.2021.109566_bib99","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2174\/1381612822666161021152322","article-title":"Ginseng in dermatology: a review","volume":"23","author":"Sabouri-Rad","year":"2017","journal-title":"Curr. Pharmaceut. Des."},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib100","doi-asserted-by":"crossref","DOI":"10.1186\/s13020-019-0279-0","article-title":"Inhibition of human carboxylesterases by ginsenosides: structure-activity relationships and inhibitory mechanism","volume":"14","author":"Sun","year":"2019","journal-title":"Chin. Med."},{"key":"10.1016\/j.cbi.2021.109566_bib101","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.phytochem.2017.08.004","article-title":"Isoflavones and anti-inflammatory constituents from the fruits of Psoralea corylifolia","volume":"143","author":"Chen","year":"2017","journal-title":"Phytochemistry"},{"issue":"6","key":"10.1016\/j.cbi.2021.109566_bib102","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/00498254.2015.1091521","article-title":"Inhibition behavior of fructus psoraleae's ingredients towards human carboxylesterase 1 (hCES1)","volume":"46","author":"Sun","year":"2016","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib103","first-page":"830","article-title":"Drug-drug interaction between clopidogrel and neobavaisoflavone, corylifolinin, and coryfolin","volume":"35","author":"Zhang","year":"2016","journal-title":"Lat. Am. J. Pharm."},{"issue":"12","key":"10.1016\/j.cbi.2021.109566_bib104","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1177\/0091270005282630","article-title":"Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use","volume":"45","author":"Zhou","year":"2005","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.cbi.2021.109566_bib105","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1021\/acs.jnatprod.8b00378","article-title":"Potent, irreversible inhibition of human carboxylesterases by tanshinone anhydrides isolated from Salvia miltiorrhiza (\"Danshen\")","volume":"81","author":"Hatfield","year":"2018","journal-title":"J. Nat. Prod."},{"issue":"6","key":"10.1016\/j.cbi.2021.109566_bib106","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ptr.2362","article-title":"Review of pharmacological effects of Glycyrrhiza sp and its bioactive compounds","volume":"22","author":"Asl","year":"2008","journal-title":"Phytother Res."},{"issue":"1","key":"10.1016\/j.cbi.2021.109566_bib107","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1039\/D0FO02140G","article-title":"Discovery of hCES2A inhibitors from Glycyrrhizae Inflatae via combination of docking-based virtual screening and fluorescence-based inhibition assays","volume":"12","author":"Song","year":"2021","journal-title":"Food & Function"},{"key":"10.1016\/j.cbi.2021.109566_bib108","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijbiomac.2019.06.235","article-title":"Discovery of a highly specific and efficacious inhibitor of human carboxylesterase 2 by large-scale screening","volume":"137","author":"Song","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"10.1016\/j.cbi.2021.109566_bib109","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jtcme.2018.01.011","article-title":"Anti-inflammatory and preventive activity of white mulberry root bark extract in an experimental model of pancreatitis","volume":"8","author":"Kavitha","year":"2018","journal-title":"J. Tradit. Complementary Med."},{"issue":"11","key":"10.1016\/j.cbi.2021.109566_bib110","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1080\/00498254.2018.1548718","article-title":"Evaluation of the inhibition of human carboxylesterases (CESs) by the active ingredients from Schisandra chinensis","volume":"49","author":"Fu","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cbi.2021.109566_bib111","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jnatprod.0c00464","article-title":"Bioactivity-guided discovery of human carboxylesterase inhibitors from the roots of paeonia lactiflora","author":"Zhang","year":"2020","journal-title":"J. Nat. Prod."},{"issue":"5","key":"10.1016\/j.cbi.2021.109566_bib112","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1124\/dmd.118.086074","article-title":"In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites","volume":"47","author":"Qian","year":"2019","journal-title":"Drug Metabol. Dispos."},{"issue":"6","key":"10.1016\/j.cbi.2021.109566_bib113","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/jsfa.4280","article-title":"Antimicrobial effect of Magnolia officinalis extract against Staphylococcus aureus","volume":"91","author":"Hu","year":"2011","journal-title":"J. Sci. Food Agric."},{"key":"10.1016\/j.cbi.2021.109566_bib114","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cbi.2019.06.003","article-title":"Inhibition of human carboxylesterases by magnolol: kinetic analyses and mechanism","volume":"308","author":"Song","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2021.109566_bib115","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ijbiomac.2018.09.178","article-title":"Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1","volume":"120","author":"Wang","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"issue":"7","key":"10.1016\/j.cbi.2021.109566_bib116","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ptr.6062","article-title":"Evidence for Shikonin acting as an active inhibitor of human carboxylesterases 2: implications for herb-drug combination","volume":"32","author":"Li","year":"2018","journal-title":"Phytother Res."},{"key":"10.1016\/j.cbi.2021.109566_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103101","article-title":"Demethylbellidifolin isolated from Swertia bimaculate against human carboxylesterase 2: kinetics and interaction mechanism merged with docking simulations","volume":"90","author":"Liu","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.cbi.2021.109566_bib118","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijbiomac.2019.04.099","article-title":"A natural inhibitor from Alisma orientale against human carboxylesterase 2: kinetics, circular dichroism spectroscopic analysis, and docking simulation","volume":"133","author":"Yi","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.cbi.2021.109566_bib119","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.fitote.2017.06.026","article-title":"Phenolic glycosides and monoterpenoids from the roots of Euphorbia ebracteolata and their bioactivities","volume":"121","author":"Wang","year":"2017","journal-title":"Fitoterapia"},{"issue":"10","key":"10.1016\/j.cbi.2021.109566_bib120","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1021\/acs.jnatprod.5b00321","article-title":"Protostane triterpenoids from the rhizome of alisma orientale exhibit inhibitory effects on human carboxylesterase 2","volume":"78","author":"Mai","year":"2015","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.cbi.2021.109566_bib121","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.phymed.2018.10.006","article-title":"Phytochemical constituents from Uncaria rhynchophylla in human carboxylesterase 2 inhibition: kinetics and interaction mechanism merged with docking simulations","volume":"51","author":"Wang","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cbi.2021.109566_bib122","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bioorg.2018.01.011","article-title":"Characterization and structure-activity relationship studies of flavonoids as inhibitors against human carboxylesterase 2","volume":"77","author":"Weng","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.cbi.2021.109566_bib123","doi-asserted-by":"crossref","first-page":"655659","DOI":"10.3389\/fphar.2021.655659","article-title":"Discovery and characterization of the biflavones from Ginkgo biloba as highly specific and potent inhibitors against human carboxylesterase 2","volume":"12","author":"Song","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"14","key":"10.1016\/j.cbi.2021.109566_bib124","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2174\/0929867325666171204155558","article-title":"Carboxylesterase inhibitors: an update","volume":"25","author":"Zou","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.cbi.2021.109566_bib125","series-title":"Carboxylesterases mediated herb-drug interactions: a systematic review","first-page":"25","author":"Wang","year":"2019"},{"issue":"3","key":"10.1016\/j.cbi.2021.109566_bib126","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpha.2020.05.006","article-title":"Original Rapid bioluminescence assay for monitoring rat CES1 activity and its alteration by traditional Chinese medicines","volume":"10","author":"Zhang","year":"2020","journal-title":"J. Pharmaceut. Anal."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib127","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nchembio.1429","article-title":"Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes","volume":"10","author":"Dominguez","year":"2014","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.cbi.2021.109566_bib128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13238-017-0437-z","article-title":"Carboxylesterases in lipid metabolism:from mouse to human","volume":"9","author":"Lian","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.cbi.2021.109566_bib129","doi-asserted-by":"crossref","first-page":"45ra59","DOI":"10.1126\/scitranslmed.3001270","article-title":"The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity","volume":"2","author":"Lam","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"13","key":"10.1016\/j.cbi.2021.109566_bib130","first-page":"4983","article-title":"Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis","volume":"9","author":"Sanghani","year":"2003","journal-title":"Clin. Canc. Res."},{"issue":"61","key":"10.1016\/j.cbi.2021.109566_bib131","doi-asserted-by":"crossref","first-page":"35904","DOI":"10.1039\/C9RA07457K","article-title":"Discovery of dihydrooxazolo 2,3-a isoquinoliniums as highly specific inhibitors of hCE2","volume":"9","author":"Ding","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.cbi.2021.109566_bib132","doi-asserted-by":"crossref","first-page":"112856","DOI":"10.1016\/j.ejmech.2020.112856","article-title":"Design, synthesis and biological evaluation of indanone-chalcone hybrids as potent and selective hCES2A inhibitors","volume":"209","author":"Huo","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2021.109566_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00435","article-title":"Structure-activity relationships of pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1","volume":"8","author":"Zou","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109566_bib134","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejmech.2016.02.020","article-title":"Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2","volume":"112","author":"Zou","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.cbi.2021.109566_bib135","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.114.056994","article-title":"Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase","volume":"42","author":"Shimizu","year":"2014","journal-title":"Drug Metabol. Dispos."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721002040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721002040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:07:39Z","timestamp":1757858859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279721002040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":135,"alternative-id":["S0009279721002040"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109566","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109566"}}